Meanwhile diabetes treatmeant Trajenta increased 23.1% to 1.1 billion euros, and recently launched pulmonary fibrosis drug Ofev is powering ahead, with sales growing 106.4% to 600,000 euros.

Its sales increased by 53% for 2018, and net sales totalled 1.8 billion euros, while Boehringer’s other big diabetes drug Trajenta saw sales increase by 9% to 1.4 billion euros. The company’s ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...